QLTI Profile
The company was a Canadian biopharmaceutical company that focused on the development and commercialization of treatments for retinal diseases, dermatological conditions, and other medical conditions.
In 2015, QLT Inc. completed a merger with another biopharmaceutical company, Auxilium Pharmaceuticals, to form a new company called Mallinckrodt plc. Following the merger, QLT Inc. shares were delisted from the Toronto Stock Exchange and the NASDAQ Stock Market.
Mallinckrodt plc, the successor company to QLT Inc., is a global specialty pharmaceutical company that focuses on the development and commercialization of treatments for autoimmune and rare diseases. The company's stock is currently listed on the New York Stock Exchange under the symbol MNK.
As of the close of trading on February 18, 2023, Mallinckrodt's stock was trading at $1.39 per share. The company has faced a number of challenges in recent years, including legal and regulatory issues related to its opioid business and financial difficulties due to declining sales of its main product, H.P. Acthar Gel.
Overall, Mallinckrodt is a company that faces significant challenges and risks, and investors should carefully consider these factors before investing in the company's stock.
|
